Global Information
회사소개 | 문의 | 비교리스트

세계의 바이러스 벡터 및 비바이러스 벡터 제조 시장(2021-2031년) : 벡터 유형, 용도, 질환, 지역별

Global Viral and Non-Viral Vector Manufacturing Market: Focus on Vector Type, Application, Disease and Region - Analysis and Forecast, 2021-2031

리서치사 BIS Research Inc.
발행일 2021년 12월 상품코드 1044192
페이지 정보 영문 배송안내 1-2일 (영업일 기준)
가격
US $ 5,250 ₩ 6,758,000 PDF (1-3 User License)
US $ 8,100 ₩ 10,427,000 PDF and Excel (Global License)


세계의 바이러스 벡터 및 비바이러스 벡터 제조 시장(2021-2031년) : 벡터 유형, 용도, 질환, 지역별 Global Viral and Non-Viral Vector Manufacturing Market: Focus on Vector Type, Application, Disease and Region - Analysis and Forecast, 2021-2031
발행일 : 2021년 12월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 바이러스 벡터 및 비바이러스 벡터 제조 시장 규모는 2020년 15억 달러에서 예측기간 중은 18.54%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2031년에는 270억 3,000만 달러에 이를 것으로 예측됩니다.

바이러스 벡터나 비바이러스 벡터는 치료비 감소나 약제 반복 투여 감소에 도움이 되는 것으로 알려져 있고, 다양한 중독(重篤) 질환을 치료하기 위한 새로운 치료법으로서 세계적으로 주목받고 있습니다. 벡터를 이용한 유전자 치료나 세포 치료 보급, 벡터를 이용한 치료에 관한 연구에 대한 자금 제공 증가 등도 시장 성장을 촉진하는 주요인이 되고 있습니다. 유전성 질환, 암, 감염증 발생률 증가, 유전자 치료, 세포 치료, 벡터 백신의 임상 연구 증가, 강력한 파이프라인도 시장 성장을 가속하는 요인입니다.

세계의 바이러스 벡터 및 비바이러스 벡터 제조 시장을 조사했으며, 시장 개요, 코로나19(COVID-19) 및 기타 시장 영향요인 분석, 특허 상황, 시장 규모 추이와 예측, 벡터 유형·질환·용도·지역/주요 국가 등 각종 구분별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 제품 정의

제2장 조사 범위

제3장 조사 방법

제4장 세계의 바이러스 벡터 및 비바이러스 벡터 제조 시장 : 시장 개요

  • 시장 개요
  • 벡터 개요
  • 벡터의 중요성
  • 벡터 제조에서의 주요 마일스톤
  • 세계의 바이러스 및 비바이러스 벡터 제조 시장 규모
  • COVID-19의 영향

제5장 시장 역학

  • 영향 분석
  • 개요
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회

제6장 산업 분석

  • 개요
  • 규제 시나리오
  • 특허 상황

제7장 경쟁 구도

  • 개요
  • 주요 전개와 전략
  • 시장 점유율 분석(기업별)
  • 성장 점유율 분석

제8장 세계의 바이러스 벡터 및 비바이러스 벡터 제조 시장 : 벡터 유형별

  • 개요
  • 바이러스 벡터
    • 아데노바이러스 벡터
    • 레트로바이러스 벡터
    • 아데노 수반 바이러스 벡터
    • 렌티바이러스 벡터
    • 백시니아바이러스 벡터
    • 기타
  • 비바이러스 벡터
    • 플라스미드 DNA
    • 지질 기반 비바이러스 벡터
    • 폴리머 기반 비바이러스 벡터
    • 기타(펩티드 기반 및 하이브리드/복합)

제9장 세계의 바이러스 벡터 및 비바이러스 벡터 제조 시장 : 질환별

  • 개요
  • 유전병
  • 감염증
  • 순환기 질환
  • 기타

제10장 세계의 바이러스 벡터 및 비바이러스 벡터 제조 시장 : 용도별

  • 개요
  • 유전자 치료
    • 바이러스 벡터
    • 비바이러스 벡터
  • 백신
    • 바이러스 벡터
    • 비바이러스 벡터
  • 세포 치료
    • 바이러스 벡터
    • 비바이러스 벡터
  • 기타
    • 바이러스 벡터
    • 비바이러스 벡터

제11장 세계의 바이러스 벡터 및 비바이러스 벡터 제조 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제12장 기업 개요

  • Boehringer Ingelheim
  • Catalent, Inc.
  • FUJIFILM Holdings Corporation
  • Danaher Corporation
  • Genscript Biotech Corporation
  • Lonza Group AG
  • Merck KGaA Inc.
  • Oxford Biomedica plc
  • Sartorius AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec
  • Acuitas Therapeutics
  • Evonik Industries AG
  • Exelead, Inc.
  • Entos Pharmaceuticals
  • Genevant Sciences GmbH
  • T&T Scientific Corporation
  • Moderna, Inc.
  • CureVac N.V.
LSH 22.01.20

List of Figures

  • Figure 1: Global Viral and Non-Viral Vector Manufacturing Market (by Region), 2020 and 2031
  • Figure 2: Key Players of the Global Viral and Non-Viral Vector Manufacturing Market
  • Figure 3: Drivers, Challenges, and Opportunities of the Global Viral Vector and Non-Viral Vector Manufacturing Market
  • Figure 4: Share of Key Developments and Strategies, January 2018-October 2021
  • Figure 5: Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type), $Million, 2020 and 2031
  • Figure 6: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 7: Global Viral and Non-Viral Vector Manufacturing Market (by Disease), 2020 and 2031
  • Figure 8: Global Viral and Non-Viral Vector Manufacturing Market (by Application), 2020 and 2031
  • Figure 9: Global Viral and Non-Viral Vector Manufacturing Market Segmentation
  • Figure 10: Global Viral and Non-Viral Vector Manufacturing Market Research Methodology
  • Figure 11: Primary Research
  • Figure 12: Secondary Research
  • Figure 13: Data Triangulation
  • Figure 14: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 15: Top-Down Approach (Segment-Wise Analysis)
  • Figure 16: Assumptions and Limitations
  • Figure 17: Mechanism of Action of Vectors
  • Figure 18: Evolutionary History of Vectors
  • Figure 19: Typical Production Methods of Viral Vectors and Plasmids
  • Figure 20: Global Viral and Non-Viral Vector Manufacturing Market, $Billion, 2020-2031
  • Figure 21: Pre- COVID-19 and Post-COVID-19 Scenario of the Global Viral and Non-Viral Vector Manufacturing Market, 2017-2025
  • Figure 22: Long, Complex, and Highly Controlled Supply Chain of Cell Therapy
  • Figure 23: Less-Complex Supply Chain of Gene Therapy
  • Figure 24: Areas of Disruption in Cell Therapy Industry
  • Figure 25: Areas of Disruption in Gene Therapy Industry
  • Figure 26: Key Areas of Disruption in Commercial Operation
  • Figure 27: Measures to Navigate Crisis Recovery
  • Figure 28: Impact Analysis
  • Figure 29: Workflow Associated with Biomanufacturing for the Commercialization of Viral and Non-Viral Vector Products
  • Figure 30: Competitive Landscape, January 2018-October 2021
  • Figure 31: Share of Key Development and Strategy, January 2018-October 2021
  • Figure 32: Share of Synergistic Activities (by Company), January 2018-October 2021
  • Figure 33: Share of Business Expansion Activities (by Company), January 2018-October 2021
  • Figure 34: Share of Product Launches (by Company), January 2018-October 2021
  • Figure 35: Share of Mergers and Acquisitions (by Company), January 2018-October 2021
  • Figure 36: Share of Other Key Developments (by Company), January 2018-October 2021
  • Figure 37: Market Share Analysis of Global Viral and Non-Viral Vector Manufacturing Market (by Company), 2020
  • Figure 38: Growth Share Analysis for Global Viral and Non-Viral Vector Manufacturing Market (by Company), 2020
  • Figure 39: Growth Share Analysis for the Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type), 2020
  • Figure 40: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Vector Type)
  • Figure 41: Global Viral and Non-Viral Vector Manufacturing Market (by Viral and Non-Viral Vector), $Million, 2020 and 2031
  • Figure 42: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020-2031
  • Figure 43: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 44: Global Viral and Non-Viral Vector Manufacturing Market for Adenoviral Vector $Million, 2020-2031
  • Figure 45: Global Viral and Non-Viral Vector Manufacturing Market for Retroviral Vector $Million, 2020-2031
  • Figure 46: Global Viral and Non-Viral Vector Manufacturing Market for Adeno-Associated Viral Vector, $Million, 2020-2031
  • Figure 47: Global Viral and Non-Viral Vector Manufacturing Market for Lentiviral Vector, 2020-2031
  • Figure 48: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinia Viral Vector, $Million, 2020-2031
  • Figure 49: Global Viral and Non-Viral Vector Manufacturing Market for Other Viral Vector, $Million, 2020-2031
  • Figure 50: Global Viral and Non-Viral Vector Manufacturing Market for Non-Viral Vectors, 2020-2031
  • Figure 51: Global Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 52: Global Viral and Non-Viral Vector Manufacturing Market for Plasmid DNA, $Million, 2020-2031
  • Figure 53: Different Types of Lipid-Based Non-Viral Vectors
  • Figure 54: Viral and Non-Viral Vector Manufacturing Market for Lipid-Based Non-Viral Vectors, $Million, 2020-2031
  • Figure 55: Different Types of Polymers Used as Delivery Systems
  • Figure 56: Viral and Non-Viral Vector Manufacturing Market for Polymer-Based Non-Viral Vector, $Million, 2020-2031
  • Figure 57: Viral and Non-Viral Vector Manufacturing Market for Other Non-Viral Vector, $Million, 2020-2031
  • Figure 58: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Disease)
  • Figure 59: Global Viral and Non-Viral Vector Manufacturing Market (by Disease)
  • Figure 60: Global Viral and Non-Viral Vector Manufacturing Market for Cancer, $Million, 2020-2031
  • Figure 61: List of Approved Human Gene Transfer Trials for Monogenic Disorders
  • Figure 62: Global Viral and Non-Viral Vector Manufacturing Market for Genetic Disease, $Million, 2020-2031
  • Figure 63: Global Viral and Non-Viral Vector Manufacturing Market for Infectious Disease, $Million, 2020-2031
  • Figure 64: Global Viral and Non-Viral Vector Manufacturing Market for Cardiovascular Disease, $Million, 2020-2031
  • Figure 65: Global Viral and Non-Viral Vector Manufacturing Market for Other Diseases, 2020-2031
  • Figure 66: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Application)
  • Figure 67: Global Viral and Non-Viral Vector Manufacturing Market (by Application), 2020 and 2031
  • Figure 68: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy, $Million, 2020-2031
  • Figure 69: Gene Therapy: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 70: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy (by Viral Vector), $Million, 2020 and 2031
  • Figure 71: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 72: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology, $Million, 2020-2031
  • Figure 73: Vaccinology: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 74: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology (by Viral Vector), $Million, 2020 and 2031
  • Figure 75: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology (by Non-Viral Vector), 2020 and 2031
  • Figure 76: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy, $Million, 2020-2031
  • Figure 77: Cell Therapy: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 78: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy (by Viral Vector), $Million, 2020 and 2031
  • Figure 79: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 80: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications, $Million, 2020-2031
  • Figure 81: Other Applications: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 82: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications (by Viral Vector), $Million, 2020 and 2031
  • Figure 83: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 84: North America: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 85: U.S.: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 86: U.S.: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 87: U.S.: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 88: U.S.: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 89: Canada: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 90: Canada: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 91: Canada: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 92: Canada: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 93: Europe: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 94: Germany: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 95: Germany: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 96: Germany: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 97: Germany: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 98: U.K.: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 99: U.K.: Viral Vs Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 100: U.K.: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 101: U.K.: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 102: France: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 103: France: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 104: France: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 105: France: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 106: Italy: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 107: Italy: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), 2020-2031
  • Figure 108: Italy: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 109: Italy: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 110: Switzerland: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 111: Switzerland: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 112: Switzerland: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 113: Switzerland: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 114: Belgium: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 115: Belgium: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 116: Belgium: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 117: Belgium: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), 2020 and 2031
  • Figure 118: Spain: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 119: Spain: Viral and Non-Viral Vector Manufacturing Market, (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 120: Spain: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 121: Spain: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 122: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 123: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 124: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 125: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 126: Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 127: China: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
  • Figure 128: China: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 129: China: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 130: China: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 131: Australia: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
  • Figure 132: Australia: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 133: Australia: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 134: Australia: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 135: Japan: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
  • Figure 136: Japan: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 137: Japan: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 138: Japan: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 139: India: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
  • Figure 140: India: Viral vs Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 141: India: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 142: India: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 143: South Korea: Viral Vector and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 144: South Korea: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 145: South Korea: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 146: South Korea: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 147: Singapore: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
  • Figure 148: Singapore: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 149: Singapore: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 150: Singapore: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020-2031
  • Figure 151: Rest-of-Asia-Pacific: Viral Vector and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 152: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral Vector), $Million, 2020-2031
  • Figure 153: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 154: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 155: Rest-of-the-World Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
  • Figure 156: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
  • Figure 157: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
  • Figure 158: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
  • Figure 159: Shares of Key Company Profiles
  • Figure 160: Boehringer Ingelheim: Service Portfolio
  • Figure 161: Boehringer Ingelheim: SWOT Analysis
  • Figure 162: Catalent, Inc.: Service/Product Portfolio
  • Figure 163: Catalent, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 164: Catalent, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 165: Catalent, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 166: Catalent, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 167: Catalent, Inc.: SWOT Analysis
  • Figure 168: FUJIFILM Holdings Corporation: Service/Product Portfolio
  • Figure 169: FUJIFILM Holdings Corporation: Overall Financials, $Million, 2018-2020
  • Figure 170: FUJIFILM Holdings Corporation: Revenue (by Segment), $Million, 2018-2020
  • Figure 171: FUJIFILM Holdings Corporation: Revenue (by Region), $Million, 2018-2020
  • Figure 172: FUJIFILM Holdings Corporation: R&D Expenditure, $Million, 2018-2020
  • Figure 173: FUJIFILM Holdings Corporation: SWOT Analysis
  • Figure 174: Danaher Corporation: Service/Product Portfolio
  • Figure 175: Danaher Corporation: Overall Financials, $Million, 2018-2020
  • Figure 176: Danaher Corporation: Revenue (by Segment), $Million, 2018-2020
  • Figure 177: Danaher Corporation: Revenue (by Region), $Million, 2018-2020
  • Figure 178: Danaher Corporation: R&D Expenditure, $Million, 2018-2020
  • Figure 179: Danaher Corporation: SWOT Analysis
  • Figure 180: Genscript Biotech Corporation: Service/Product Portfolio
  • Figure 181: Genscript Biotech Corporation: Overall Financials, $Million, 2018-2020
  • Figure 182: Genscript Biotech Corporation: Revenue (by Segment), $Million, 2018-2020
  • Figure 183: Genscript Biotech Corporation: Revenue (by Region), $Million, 2018-2020
  • Figure 184: Genscript Biotech Corporation: R&D Expenditure, $Million, 2018-2020
  • Figure 185: Genscript Biotech Corporation: SWOT Analysis
  • Figure 186: Lonza Group AG: Service/Product Portfolio
  • Figure 187: Lonza Group AG: Overall Financials, $Million, 2018-2020
  • Figure 188: Lonza Group AG: Revenue (by Segment), $Million, 2018-2020
  • Figure 189: Lonza Group AG: Revenue (by Region), $Million, 2018-2020
  • Figure 190: Lonza Group AG: R&D Expenditure, $Million, 2018-2020
  • Figure 191: Lonza Group AG: SWOT Analysis
  • Figure 192: Merck KGaA Inc.: Service/Product Portfolio
  • Figure 193: Merck KGaA Inc.: Overall Financials, $Million, 2018-2020
  • Figure 194: Merck KGaA Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 195: Merck KGaA Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 196: Merck KGaA Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 197: Merck KGaA Inc.: SWOT Analysis
  • Figure 198: Oxford Biomedica plc: Service/Product Portfolio
  • Figure 199: Oxford Biomedica plc: Overall Financials, $Million, 2018-2020
  • Figure 200: Oxford Biomedica plc: Revenue (by Segment), $Million, 2018-2020
  • Figure 201: Oxford Biomedica plc: Revenue (by Region), $Million, 2018-2020
  • Figure 202: Oxford Biomedica plc: R&D Expenditure, $Million, 2018-2020
  • Figure 203: Oxford Biomedica plc: SWOT Analysis
  • Figure 204: Sartorius AG: Service/Product Portfolio
  • Figure 205: Sartorius AG: Overall Financials, $Million, 2018-2020
  • Figure 206: Sartorius AG: Revenue (by Segment), $Million, 2018-2020
  • Figure 207: Sartorius AG: Revenue (by Region), $Million, 2018-2020
  • Figure 208: Sartorius AG: R&D Expenditure, $Million, 2018-2020
  • Figure 209: Sartorius AG: SWOT Analysis
  • Figure 210: Takara Bio Inc.: Service/Product Portfolio
  • Figure 211: Takara Bio Inc.: Overall Financials, $Million, 2018-2020
  • Figure 212: Takara Bio Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 213: Takara Bio Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 214: Takara Bio Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 215: Takara Bio Inc.: SWOT Analysis
  • Figure 216: Thermo Fisher Scientific, Inc.: Service/Product Portfolio
  • Figure 217: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 218: Thermo Fisher Scientific, Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 219: Thermo Fisher Scientific, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 220: Thermo Fisher Scientific, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 221: Thermo Fisher Scientific, Inc.: SWOT Analysis
  • Figure 222: Wuxi AppTec: Service/Product Portfolio
  • Figure 223: Wuxi AppTec: Overall Financials, $Million, 2018-2020
  • Figure 224: Wuxi AppTec: Revenue (by Segment), $Million, 2018-2020
  • Figure 225: Wuxi AppTec: Revenue (by Region), $Million, 2018-2020
  • Figure 226: Wuxi AppTec: R&D Expenditure, $Million, 2018-2020
  • Figure 227: Wuxi AppTec: SWOT Analysis
  • Figure 228: Acuitas Therapeutics: Service/Product Portfolio
  • Figure 229: Acuitas Therapeutics: SWOT Analysis
  • Figure 230: Evonik Industries AG: Service/Product Portfolio
  • Figure 231: Evonik Industries AG: Overall Financials, $Million, 2018-2020
  • Figure 232: Evonik Industries AG: Revenue (by Segment), $Million, 2018-2020
  • Figure 233: Evonik Industries AG: Revenue (by Region), $Million, 2018-2020
  • Figure 234: Evonik Industries AG: R&D Expenditure, $Million, 2018-2020
  • Figure 235: Evonik Industries AG: SWOT Analysis
  • Figure 236: Exelead, Inc.: Service/Product Portfolio
  • Figure 237: Exelead, Inc.: SWOT Analysis
  • Figure 238: Entos Pharmaceuticals: Service/Product Portfolio
  • Figure 239: Entos Pharmaceuticals: SWOT Analysis
  • Figure 240: Genevant Sciences GmbH: Service/Product Portfolio
  • Figure 241: Genevant Sciences GmbH: SWOT Analysis
  • Figure 242: T&T Scientific Corporation: Service/Product Portfolio
  • Figure 243: T&T Scientific Corporation: SWOT Analysis
  • Figure 244: Moderna, Inc.: Service/Product Portfolio
  • Figure 245: Moderna, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 246: Moderna, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 247: Moderna, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 248: Moderna, Inc.: SWOT Analysis
  • Figure 249: CureVac N.V.: Product Portfolio
  • Figure 250: CureVac N.V.: Overall Financials, $Million, 2018-2020
  • Figure 251: CureVac N.V.: Revenue (by Region), $Million, 2018-2020
  • Figure 252: CureVac N.V.: R&D Expenditure, $Million, 2018-2020
  • Figure 253: CureVac N.V.: SWOT Analysis

List of Tables

  • Table 1: Leading Segments of the Global Viral and Non-Viral Vector Manufacturing Market, 2020 and 2031
  • Table 2: Advantages and Disadvantages of Viral Vectors
  • Table 3: Advantages and Disadvantages of Non-Viral Vectors
  • Table 4: COVID-19 Candidate Viral Vector Vaccines in Clinical Stage (as of 31st July 2020)
  • Table 5: COVID-19 Candidate Viral Vector Vaccines in Preclinical Stage (as of 31 July 2020)
  • Table 6: Recent Approvals for Gene Therapy
  • Table 7: Companies Offering Gene Therapies and Their Cost
  • Table 8: Global Regulatory Scenario
  • Table 9: Patents Related to Viral Vectors (January 2018-February 2021)
  • Table 10: Patents Related to Non-Viral Vectors (January 2018-February 2021)
  • Table 11: Examples of Viral Vectors Used in Gene Therapy
  • Table 12: List of Non-Viral Vector-Based Vaccines against Infectious Diseases
  • Table 13: Features of Vectors Used in Cardiovascular Therapy
  • Table 14: Examples of Clinical Trials Using Viral Vectors
  • Table 15: List of Clinical Trials Using Non-Viral Vectors
  • Table 16: Advantages and Disadvantages Associated with Major Viral Vectors

“Global Viral and Non-Viral Vector Manufacturing Market to Reach $27.03 Billion by 2031.”

Market Report Coverage - Viral and Non-Viral Vector Manufacturing

Market Segmentation

  • Vector Type - Viral Vector and Non-Viral Vector
  • Disease - Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
  • Application - Gene Therapy, Vaccinology, Cell Therapy, and Other Applications

Regional Segmentation

  • North America: U.S., Canada
  • Europe: Germany, U.K., France, Italy, Switzerland, Belgium, Spain, and Rest-of-Europe
  • Asia-Pacific: China, India, Japan, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
  • Rest-of-the-World

Market Growth Drivers

  • Rapid Uptake of Viral Vector to Develop Innovative Therapies
  • Increasing Number of Clinical Studies for the Development of Gene Therapy
  • Favorable Funding Scenario for Vector-Based Therapies
  • Increasing Adoption of Nucleic Acid Therapeutics
  • Rise in Synergistic Activities in the Market

Market Challenges

  • Unaffordable Cost of Gene Therapy
  • High Manufacturing Cost of Viral Vectors
  • Complications Associated with Large-Scale Production of Viral Vectors
  • Low Transfection Efficiency

Market Opportunities

  • Rise in Demand for Synthetic Genes
  • Emergence of Next-Generation Vectors
  • Limitation of Viral Vectors

Key Companies Profiled

Boehringer Ingelheim, Catalent, Inc., FUJIFILM Holdings Corporation, Danaher Corporation, Genscript Biotech Corporation, Lonza Group AG, Merck KGaA Inc., Oxford Biomedica plc, Sartorius AG, Takara Bio Inc., Thermo Fisher Scientific Inc., Wuxi AppTec, Acuitas Therapeutics, Evonik Industries AG, Exelead, Inc., Entos Pharmaceuticals, Genevant Sciences GmbH, T&T Scientific Corporation, Moderna, Inc., CureVac N.V.

Key Questions Answered in this Report:

  • What is a vector, and what is its importance in the medical industry? What are the major characteristics and types of vectors? What are the areas of application of vectors?
  • What are the major advancements in viral and non-viral vector manufacturing? What are the key trends of the global viral and non-viral vector manufacturing market? How is the market evolving, and what is its future scope?
  • What are the major drivers, challenges, and opportunities of the global viral and non-viral vector manufacturing market?
  • What are the key developmental strategies implemented by the key players of the global viral and non-viral vector manufacturing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
  • What is the regulatory scenario of the global viral and non-viral vector manufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of viral and non-viral vector manufacturing products?
  • What are major milestones in patenting activity in the global viral and non-viral vector manufacturing market?
  • What was the market size of the global viral and non-viral vector manufacturing market in 2020, and what is the market size anticipated to be by 2031? What is the expected growth rate of the global viral and non-viral vector manufacturing market during the forecast period 2021-2031?
  • What is the global market size for manufacturing different types of viral and non-viral vectors available in the global viral and non-viral vector manufacturing market? What are the key trends of the market with respect to different vectors, and which vector type is expected to dominate the market in 2031?
  • What are the different disease areas where non-viral vectors and viral vectors are employed in the global viral and non-viral vector manufacturing market? Which disease type dominated the market in 2020 and is expected to dominate in 2031?
  • What are the different applications associated with the viral vector and non-viral vector manufacturing? What was the contribution of each of the application areas in the global viral and non-viral vector manufacturing market in 2020, and what is it expected in 2031?
  • Which region is expected to contribute the highest sales in the global viral and non-viral vector manufacturing market during the period 2021-2031? Which region and country carries the potential for the significant expansion of key companies for different viral and non-viral vector manufacturing? What are the leading countries of different regions that contribute significantly toward the growth of the viral and non-viral manufacturing market?
  • What are the key players of the global viral and non-viral vector manufacturing market, and what are their roles in the market? What were the market shares of the key players in 2020?

Market Overview

The advent of advanced therapies, including gene therapy and cell therapy, which employ the use of vectors, has created a huge impact in the field of medicine in the past few decades. Therapies that require genetic modification, including the introduction of therapeutic deoxyribonucleic acid (DNA)/gene into a patient's body or cell, demonstrated tremendous potential for treating several fatal diseases, including cancer, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis, among others. Promising results displayed by these vector-based therapies in several preclinical and clinical studies have further emphasized the development and standardization of various viral and non-viral vectors to address unmet medical needs. The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.

Known to reduce the cost of treatment and help decrease repeated administration of medications, viral vectors, and non-viral vectors have gained significant attention globally as a novel therapeutic approach for treating various critical diseases, thereby promoting a surge of investments in drug development and commercialization. Growing prominence of gene and cell therapy products (that utilize vectors) and increasing funding activities driving research related to vector-based therapies are the key driving factors fuelling the growth of the global viral and non-viral vector manufacturing market. Moreover, rising incidences of genetic disorders, cancers, and infectious diseases, coupled with the increasing number of clinical studies and robust pipeline of gene and cell therapy products as well as vector-based vaccines, are the additional driving factors encouraging market growth.

Competitive Landscape

The global viral and non-viral vector manufacturing market comprises well-established and newly emerging companies. Several companies are attempting to enter the market and sustain the competition by adopting synergistic activities and expanding their business by launching manufacturing capacities or developing proprietary viral and non-viral vector platforms.

In the past three years (2018-2020), the key market players of the global viral and non-viral vector manufacturing market witnessed majorly synergistic activities, business expansion, and funding activities. The inclination of companies toward synergies suggests that the companies are collaborating with viral and non-viral vector manufacturers to develop novel cell therapies, gene therapies, and vaccines for various diseases. The expansion of manufacturing capacities suggests that the companies are trying to fulfill the increased demand for vectors for cell and gene therapies.

Table of Contents

1 Product Definition

  • 1.1 Product Definition

2 Scope of Study

  • 2.1 Overview
  • 2.2 Segmentation of the Global Viral and Non-Viral Vector Manufacturing Market
  • 2.3 Assumptions and Limitations
  • 2.4 Key Questions Answered in This Report
  • 2.5 Base Year and Forecast Period

3 Research Methodology

  • 3.1 Overview

4 Global Viral and Non-Viral Vector Manufacturing: Market Overview

  • 4.1 Market Overview
  • 4.2 Introduction to Vectors
  • 4.3 Importance of Vectors
    • 4.3.1 Viral Vectors
    • 4.3.2 Non-Viral Vectors
  • 4.4 Major Milestones in Vector Manufacturing
    • 4.4.1 Manufacturing Process
      • 4.4.1.1 Upstream Bioprocessing
      • 4.4.1.2 Downstream Bioprocessing
  • 4.5 Global Viral and Non-Viral Vector Manufacturing Market Size
  • 4.6 Impact of COVID-19 on the Global Viral and Non-Viral Vector Manufacturing Market
    • 4.6.1 Disruption of the Vector Manufacturing Industry Due to COVID-19 Crisis
    • 4.6.2 COVID-19 Affecting the Supply Chain of Vector-Based Therapies
      • 4.6.2.1 Effect on Cell Therapy
      • 4.6.2.2 Effect on Gene Therapy
    • 4.6.3 Interruption in Research and Clinical Development and Commercial Operation
      • 4.6.3.1 Research and Clinical Development
      • 4.6.3.2 Commercial Operation and Access
    • 4.6.4 Effect of COVID-19 in Vaccine Manufacturing
    • 4.6.5 Measures Taken to Address the Current Problem
    • 4.6.6 Navigating Crisis Recovery and Looking to the Future

5 Market Dynamics

  • 5.1 Impact Analysis
  • 5.2 Overview
  • 5.3 Market Drivers
    • 5.3.1 Viral Vectors
      • 5.3.1.1 Rapid Uptake of Viral Vector to Develop Innovative Therapies
      • 5.3.1.2 Increasing Number of Clinical Studies for the Development of Gene Therapy
      • 5.3.1.3 Favorable Funding Scenario for Vector-Based Therapies
    • 5.3.2 Non-Viral Vectors
      • 5.3.2.1 Increasing Adoption of Nucleic Acid Therapeutics
      • 5.3.2.2 Rise in Synergistic Activities in the Market
  • 5.4 Market Restraints
    • 5.4.1 Viral Vectors
      • 5.4.1.1 Unaffordable Cost of Gene Therapy
      • 5.4.1.2 High Manufacturing Cost of Viral Vectors
      • 5.4.1.3 Complications Associated with Large-Scale Production of Viral Vectors
    • 5.4.2 Non-Viral Vectors
      • 5.4.2.1 Low Transfection Efficiency
  • 5.5 Market Opportunities
    • 5.5.1 Viral Vectors
      • 5.5.1.1 Rise in Demand for Synthetic Genes
      • 5.5.1.2 Emergence of Next-Generation Vectors
    • 5.5.2 Non-Viral Vectors
      • 5.5.2.1 Limitation of Viral Vectors

6 Industry Analysis

  • 6.1 Overview
  • 6.2 Regulatory Scenario
  • 6.3 Patent Landscape

7 Competitive Landscape

  • 7.1 Overview
  • 7.2 Key Development and Strategies
    • 7.2.1 Synergistic Activities
    • 7.2.2 Business Expansion
    • 7.2.3 Product Launches
    • 7.2.4 Mergers and Acquisitions
    • 7.2.5 Other Development
  • 7.3 Market Share Analysis (by Company), 2020
  • 7.4 Growth Share Analysis
    • 7.4.1 Growth Share Analysis of the Global Viral and Non-Viral Vector Manufacturing Market (by Company)
    • 7.4.2 Growth Share Analysis of the Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type)

8 Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type)

  • 8.1 Overview
  • 8.2 Viral Vector
    • 8.2.1 Adenoviral Vector
    • 8.2.2 Retroviral Vector
    • 8.2.3 Adeno-Associated Viral Vector
    • 8.2.4 Lentiviral Vector
    • 8.2.5 Vaccinia Viral Vector
    • 8.2.6 Other Viral Vector
  • 8.3 Non-Viral Vectors
    • 8.3.1 Plasmid DNA
    • 8.3.2 Lipid-Based Non-Viral Vector
    • 8.3.3 Polymer-Based Non-Viral Vector
    • 8.3.4 Other Non-Viral Vector (Peptide-Based and Hybrid/Combination)

9 Global Viral and Non-Viral Vector Manufacturing Market (by Disease)

  • 9.1 Overview
  • 9.2 Cancer
  • 9.3 Genetic Disease
  • 9.4 Infectious Disease
  • 9.5 Cardiovascular Disease
  • 9.6 Other Diseases

10 Global Viral and Non-Viral Vector Manufacturing Market (by Application)

  • 10.1 Overview
  • 10.2 Gene Therapy
    • 10.2.1 Viral Vector
    • 10.2.2 Non-Viral Vector
  • 10.3 Vaccinology
    • 10.3.1 Viral Vector
    • 10.3.2 Non-Viral Vector
  • 10.4 Cell Therapy
    • 10.4.1 Viral Vector
    • 10.4.2 Non-Viral Vector
  • 10.5 Other Applications
    • 10.5.1 Viral Vector
    • 10.5.2 Non-Viral Vector

11 Global Viral and Non-Viral Vector Manufacturing Market (by Region)

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 Overview
    • 11.2.2 U.S.
      • 11.2.2.1 Viral Vector
      • 11.2.2.2 Non-Viral Vector
    • 11.2.3 Canada
      • 11.2.3.1 Viral Vector
      • 11.2.3.2 Non-Viral Vector
  • 11.3 Europe
    • 11.3.1 Overview
    • 11.3.2 Germany
      • 11.3.2.1 Viral Vector
      • 11.3.2.2 Non-Viral Vector
    • 11.3.3 U.K.
      • 11.3.3.1 Viral Vector
      • 11.3.3.2 Non-Viral Vector
    • 11.3.4 France
      • 11.3.4.1 Viral Vector
      • 11.3.4.2 Non-Viral Vector
    • 11.3.5 Italy
      • 11.3.5.1 Viral Vector
      • 11.3.5.2 Non-Viral Vector
    • 11.3.6 Switzerland
      • 11.3.6.1 Viral Vector
      • 11.3.6.2 Non-Viral Vector
    • 11.3.7 Belgium
      • 11.3.7.1 Viral Vector
      • 11.3.7.2 Non-Viral Vector
    • 11.3.8 Spain
      • 11.3.8.1 Viral Vector
      • 11.3.8.2 Non-Viral Vector
    • 11.3.9 Rest-of-Europe
      • 11.3.9.1 Viral Vector
      • 11.3.9.2 Non-Viral Vector
  • 11.4 Asia-Pacific
    • 11.4.1 Overview
    • 11.4.2 China
      • 11.4.2.1 Viral Vector
      • 11.4.2.2 Non-Viral Vector
    • 11.4.3 Australia
      • 11.4.3.1 Viral Vector
      • 11.4.3.2 Non-Viral Vector
    • 11.4.4 Japan
      • 11.4.4.1 Viral Vector
      • 11.4.4.2 Non-Viral Vector
    • 11.4.5 India
      • 11.4.5.1 Viral Vector
      • 11.4.5.2 Non-Viral Vector
    • 11.4.6 South Korea
      • 11.4.6.1 Viral Vector
      • 11.4.6.2 Non-Viral Vector
    • 11.4.7 Singapore
      • 11.4.7.1 Viral Vector
      • 11.4.7.2 Non-Viral Vector
    • 11.4.8 Rest-of-Asia-Pacific
      • 11.4.8.1 Viral Vector
      • 11.4.8.2 Non-Viral Vector
  • 11.5 Rest-of-the-World
    • 11.5.1 Overview
      • 11.5.1.1 Viral Vector
      • 11.5.1.2 Non-Viral Vector

12 Company Profiles

  • 12.1 Overview
  • 12.2 Boehringer Ingelheim
    • 12.2.1 Company Overview
      • 12.2.1.1 Role of Boehringer Ingelheim in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.2.1.2 Product Portfolio
    • 12.2.2 SWOT Analysis
  • 12.3 Catalent, Inc.
    • 12.3.1 Company Overview
      • 12.3.1.1 Role of Catalent, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.3.1.2 Product Portfolio
    • 12.3.2 Financials
    • 12.3.3 Key Insights about Financial Health of the Company
    • 12.3.4 SWOT Analysis
  • 12.4 FUJIFILM Holdings Corporation
    • 12.4.1 Company Overview
      • 12.4.1.1 Role of FUJIFILM Holdings Corporation in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.4.1.2 Product Portfolio
    • 12.4.2 Financials
    • 12.4.3 Key Insights about Financial Health of the Company
    • 12.4.4 SWOT Analysis
  • 12.5 Danaher Corporation
    • 12.5.1 Company Overview
    • 12.5.2 Role of Danaher Corporation in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.5.2.1 Product Portfolio
    • 12.5.3 Financials
    • 12.5.4 Key Insights about Financial Health of the Company
    • 12.5.5 SWOT Analysis
  • 12.6 Genscript Biotech Corporation
    • 12.6.1 Company Overview
      • 12.6.1.1 Role of Genscript Biotech Corporation in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.6.1.2 Product Portfolio
    • 12.6.2 Financials
    • 12.6.3 Key Insights about Financial Health of the Company
    • 12.6.4 SWOT Analysis
  • 12.7 Lonza Group AG
    • 12.7.1 Company Overview
      • 12.7.1.1 Role of Lonza Group AG in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.7.1.2 Product Portfolio
    • 12.7.2 Financials
    • 12.7.3 Key Insights about Financial Health of the Company
    • 12.7.4 SWOT Analysis
  • 12.8 Merck KGaA Inc.
    • 12.8.1 Company Overview
      • 12.8.1.1 Role of Merck KGaA Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.8.1.2 Product Portfolio
    • 12.8.2 Financials
    • 12.8.3 Key Insights about Financial Health of the Company
    • 12.8.4 SWOT Analysis
  • 12.9 Oxford Biomedica plc
    • 12.9.1 Company Overview
      • 12.9.1.1 Role of Oxford Biomedica plc in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.9.1.2 Product Portfolio
    • 12.9.2 Financials
    • 12.9.3 Key Insights about Financial Health of the Company
    • 12.9.4 SWOT Analysis
  • 12.1 Sartorius AG
    • 12.10.1 Company Overview
      • 12.10.1.1 Role of Sartorius AG in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.10.1.2 Product Portfolio
    • 12.10.2 Financials
    • 12.10.3 Key Insights about Financial Health of the Company
    • 12.10.4 SWOT Analysis
  • 12.11 Takara Bio Inc.
    • 12.11.1 Company Overview
      • 12.11.1.1 Role of Takara Bio Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.11.1.2 Product Portfolio
    • 12.11.2 Financials
    • 12.11.3 Key Insights about Financial Health of the Company
    • 12.11.4 SWOT Analysis
  • 12.12 Thermo Fisher Scientific Inc.
    • 12.12.1 Company Overview
      • 12.12.1.1 Role of Thermo Fisher Scientific, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.12.1.2 Product Portfolio
    • 12.12.2 Financials
    • 12.12.3 Key Insights about Financial Health of the Company
    • 12.12.4 SWOT Analysis
  • 12.13 Wuxi AppTec
    • 12.13.1 Company Overview
      • 12.13.1.1 Role of Wuxi AppTec in Global Viral and Non-Viral Vector Manufacturing Market
      • 12.13.1.2 Product Portfolio
    • 12.13.2 Financials
    • 12.13.3 Key Insights about Financial Health of the Company
    • 12.13.4 SWOT Analysis
  • 12.14 Acuitas Therapeutics
    • 12.14.1 Company Overview
      • 12.14.1.1 Role of Acuitas Therapeutics in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.14.1.2 Product Portfolio
    • 12.14.2 SWOT Analysis
  • 12.15 Evonik Industries AG
    • 12.15.1 Company Overview
      • 12.15.1.1 Role of Evonik Industries AG in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.15.1.2 Product Portfolio
    • 12.15.2 Financials
    • 12.15.3 Key Insights about Financial Health of the Company
    • 12.15.4 SWOT Analysis
  • 12.16 Exelead, Inc.
    • 12.16.1 Company Overview
      • 12.16.1.1 Role of Exelead, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.16.1.2 Product Portfolio
    • 12.16.2 SWOT Analysis
  • 12.17 Entos Pharmaceuticals
    • 12.17.1 Company Overview
      • 12.17.1.1 Role of Entos Pharmaceuticals in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.17.1.2 Product Portfolio
    • 12.17.2 SWOT Analysis
  • 12.18 Genevant Sciences GmbH
    • 12.18.1 Company Overview
      • 12.18.1.1 Role of Genevant Sciences GmbH in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.18.1.2 Product Portfolio
    • 12.18.2 SWOT Analysis
  • 12.19 T&T Scientific Corporation
    • 12.19.1 Company Overview
      • 12.19.1.1 Role of T&T Scientific Corporation in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.19.1.2 Product Portfolio
    • 12.19.2 SWOT Analysis
  • 12.2 Moderna, Inc.
    • 12.20.1 Company Overview
      • 12.20.1.1 Role of Moderna, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.20.1.2 Product Portfolio
    • 12.20.2 Financials
    • 12.20.3 Key Insights about Financial Health of the Company
    • 12.20.4 SWOT Analysis
  • 12.21 CureVac N.V.
    • 12.21.1 Company Overview
      • 12.21.1.1 Role of CureVac N.V in the Global Viral and Non-Viral Vector Manufacturing Market
      • 12.21.1.2 Product Portfolio
    • 12.21.2 Financials
    • 12.21.3 Key Insights about Financial Health of the Company
    • 12.21.4 SWOT Analysis
Back to Top
전화 문의
F A Q